International Stem
Cell Corp. was the first to develop and perfect a new class of human stem cells
called parthenogenetic stem cells, which are created from unfertilized human
eggs. The company’s stem cells present superior immune matching capabilities and
can be used in millions of people regardless of sex or racial background, with
minimal expectation of immune rejection after transplantation.
Based on this stem
cell technology, ISCO is currently focused on three key therapeutic programs to
treat incurable diseases of the brain, liver, and cornea.
Parkinson’s disease
is the second most prevalent neurodegenerative diseases, affecting
approximately 4 percent of the population aged 50 years and older. Leveraging
its key clinical research agreement with Duke University, ISCO is evaluating
its stem cell-derived neural stem cells for the treatment of Parkinson’s
disease. The company has coordinated a team of leading experts to develop
techniques and designs as well as to provide guidance for the company’s investigational
new drug (IND) submission for this indication. ISCO plans on submitting its IND
to the FDA this year.
Chronic liver
disease (including hepatitis C) is the third most common cause of death due to
chronic diseases in persons 35 to 64 years old. Direct health care expenditures
for chronic and acute liver disease in the U.S. alone range from $60 billion to
more than $100 billion annually.
ISCO’s scientific
team is developing superior methods to create pure populations of hepatocyte,
the main tissue of the liver, that could be used in transplantation using HLA
homozygous parthenogenetic stem cell lines to avoid the cells being immune
rejected by the recipient’s body.
Approximately 10
million people in the world are blind due to corneal damage, representing a
large unmet medical need, mostly in the developing world. Additionally, there
is an opportunity to develop corneas as a research product for the drug testing
market. Scientists at ISCO have developed and filed patents on a process that
creates human corneal tissue from parthenogenetic stem cells. It is anticipated
that this program will be commercialized through ISCO’s subsidiary in India in
partnership with the Insight Bioventures, India.
Through continued
enrollment of egg donors and ongoing optimization of its methodology for the
creation of additional HLA homozygous lines, ISCO is expanding its bank of
parthenogenetic stem cell lines, which are critical to the success of the
company’s therapeutic programs.
For more information
visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment